Adial Pharmaceuticals, Inc.

GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. (“Azora”), which was previously announced by the Company on June 11, 2026.

globenewswire.com - 2026-06-16 08:00:00

- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027

globenewswire.com - 2026-06-11 11:43:00

GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026.

globenewswire.com - 2026-05-11 08:30:00

New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach

globenewswire.com - 2026-04-29 09:07:00

GLEN ALLEN, Va. , April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the submission of the AD04 product application for consideration of the Food and Drug Administration (FDA) Commissioner's National Priority Voucher Pilot Program (CNPV).

globenewswire.com - 2026-04-27 08:47:00

Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatments inadequately address patient outcomes Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatments inadequately address patient outcomes

globenewswire.com - 2026-04-27 08:47:00

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 49,013 shares, a decrease of 49.4% from the March 31st total of 96,887 shares. Currently, 3.5% of the company's stock are short sold.

defenseworld.net - 2026-04-26 03:13:06

Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production

globenewswire.com - 2026-04-22 09:35:00

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 96,887 shares, a growth of 21.7% from the March 15th total of 79,609 shares. Currently, 6.9% of the shares of the company are sold short. Based

defenseworld.net - 2026-04-17 01:36:46